NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (DRC) has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. This registration follows the company's receipt of local regulatory approval from ACOREP to begin the trial, and the drug has already been delivered to the clinical trial site in Ituri province. First patient dosing is anticipated within one to two weeks, barring outbreak-related impediments.
The adaptive trial will begin with a single-arm safety and dose run-in before progressing to a randomized, controlled, open-label efficacy evaluation. This design allows for flexibility and efficiency in assessing the drug's safety and efficacy in a challenging outbreak setting.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. It is also being evaluated in a Phase II clinical trial for Mpox in the DRC, highlighting its potential against multiple viral threats. The registration of this Ebola trial is a critical milestone for NanoViricides, as it advances the development of a novel antiviral that could address significant unmet medical needs in regions affected by recurrent Ebola outbreaks.
The implications of this trial are substantial. Ebola viruses cause severe, often fatal illness in humans, and current treatments are limited. If successful, NV-387 could provide a much-needed oral therapeutic option that is easier to administer than existing intravenous treatments, potentially improving patient outcomes and facilitating broader access in resource-limited settings. Moreover, the broad-spectrum nature of NV-387 suggests it could be effective against multiple viral families, making it a valuable asset in pandemic preparedness and response.
NanoViricides is also developing other drug candidates, including NV-HHV-1 for shingles, and has a pipeline addressing various viral diseases such as influenza, HIV, Hepatitis, and more. The company's platform technology, based on TheraCour nanomedicine, enables the creation of nanoviricide drug candidates that target viruses specifically.
The company's progress with NV-387 in both Ebola and Mpox trials underscores its commitment to addressing global health challenges. As the trial proceeds, stakeholders will be watching for safety and efficacy data that could pave the way for regulatory approvals and eventual commercialization. The outcome of this trial could have far-reaching effects on how Ebola outbreaks are managed and set a precedent for the use of broad-spectrum antivirals in emerging infectious diseases.
